DK200000687A - Middel til forsøgelse af afgivelsen af cerebral acetylcholin - Google Patents

Middel til forsøgelse af afgivelsen af cerebral acetylcholin Download PDF

Info

Publication number
DK200000687A
DK200000687A DK200000687A DKPA200000687A DK200000687A DK 200000687 A DK200000687 A DK 200000687A DK 200000687 A DK200000687 A DK 200000687A DK PA200000687 A DKPA200000687 A DK PA200000687A DK 200000687 A DK200000687 A DK 200000687A
Authority
DK
Denmark
Prior art keywords
delivery
attempting
agent
cerebral acetylcholine
cerebral
Prior art date
Application number
DK200000687A
Other languages
English (en)
Inventor
Nakamura Kazuo
Shirane Masatoshi
Tanaka Yushiro
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of DK200000687A publication Critical patent/DK200000687A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

PATENTKRAV 1. Anvendelse af N-anisoyl-GABA eller p-anissyre til fremstilling af et farmaceutisk præparat, der omfatter N-anisoyl-GABA eller p-anissyre, til at forøge afgivelsen af cerebral acet-ylcholin. 2. Anvendelse ifølge krav 1, hvor det farmaceutiske præparat er til behandling af døgn-rytmeforstyrrelser, søvnforstyrrelser, lidelser forbundet med opmærksomhedssvigt og adfærdsproblemer. 3. Anvendelse ifølge krav 1 eller krav 2, hvor N-anisoyl-GABA eller p-anissyre som effektiv bestanddel foreligger i en enhedsdosis på fra 1 til 300 mg/kg pr. voksen pr. dag. 4. Farmaceutisk præparat til at forøge afgivelsen af cerebral acetylcholin, hvilket præparat omfatter N-anisoyl-GABA eller p-anissyre som effektiv bestanddel og en terapeutisk inert bærer. 5. Farmaceutisk præparat ifølge krav 4 til behandling af døgnrytmeforstyrrelser, søvnforstyrrelser, lidelser forbundet med opmærksomhedssvigt og adfærdsproblemer. 6. Farmaceutisk præparat ifølge krav 4 eller krav 5, hvor den aktive bestanddel N-anisoyl-GABA eller p-anissyre administreres i en dosis på fra 1 til 300 mg/kg pr. voksen pr. dag.
DK200000687A 1999-04-27 2000-04-25 Middel til forsøgelse af afgivelsen af cerebral acetylcholin DK200000687A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99108223 1999-04-27

Publications (1)

Publication Number Publication Date
DK200000687A true DK200000687A (da) 2000-10-28

Family

ID=8238054

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200000687A DK200000687A (da) 1999-04-27 2000-04-25 Middel til forsøgelse af afgivelsen af cerebral acetylcholin

Country Status (24)

Country Link
US (1) US20030073744A1 (da)
JP (1) JP2000309529A (da)
KR (1) KR100372906B1 (da)
CN (1) CN1277019A (da)
AR (1) AR023763A1 (da)
AT (1) AT408836B (da)
AU (1) AU3011300A (da)
BE (1) BE1013314A3 (da)
BR (1) BR0002381A (da)
CA (1) CA2307022A1 (da)
DE (1) DE10020237A1 (da)
DK (1) DK200000687A (da)
ES (1) ES2176078A1 (da)
FI (1) FI20000977A7 (da)
FR (1) FR2792833B1 (da)
GB (1) GB2351662A (da)
GR (1) GR1003591B (da)
IE (1) IE20000308A1 (da)
IT (1) IT1318490B1 (da)
NL (1) NL1015043C2 (da)
PT (1) PT102456B (da)
SE (1) SE0001499L (da)
TR (1) TR200001133A2 (da)
ZA (1) ZA200002041B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5273731B2 (ja) * 2009-08-11 2013-08-28 独立行政法人産業技術総合研究所 生体リズムの制御剤
EP3878287B1 (en) * 2018-11-13 2026-03-11 Peng, Xianfeng Application of acylated derivative of amino acid in preparation of animal feed additive

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU21107A3 (es) * 1978-02-10 1988-02-01 Hoffmann La Roche Pyrrolidines derivatives
JPH1081607A (ja) * 1996-09-06 1998-03-31 Kamiyama:Kk 抗菌剤
JPH1081626A (ja) * 1996-09-06 1998-03-31 Kamiyama:Kk チロシナーゼ活性阻害剤

Also Published As

Publication number Publication date
ES2176078A1 (es) 2002-11-16
ITMI20000914A0 (it) 2000-04-21
TR200001133A2 (tr) 2000-11-21
SE0001499L (sv) 2000-10-28
GB2351662A (en) 2001-01-10
GB0010049D0 (en) 2000-06-14
ATA7162000A (de) 2001-08-15
FR2792833B1 (fr) 2002-09-06
AR023763A1 (es) 2002-09-04
PT102456B (pt) 2003-04-30
ZA200002041B (en) 2000-10-27
CN1277019A (zh) 2000-12-20
IE20000308A1 (en) 2000-11-29
DE10020237A1 (de) 2001-02-08
FI20000977L (fi) 2000-10-27
NL1015043C2 (nl) 2001-03-30
KR100372906B1 (ko) 2003-02-17
GR20000100145A (el) 2000-12-29
IT1318490B1 (it) 2003-08-25
ITMI20000914A1 (it) 2001-10-21
JP2000309529A (ja) 2000-11-07
NL1015043A1 (nl) 2000-10-30
KR20010029658A (ko) 2001-04-06
FR2792833A1 (fr) 2000-11-03
CA2307022A1 (en) 2000-10-27
PT102456A (pt) 2000-11-30
AT408836B (de) 2002-03-25
BE1013314A3 (fr) 2001-11-06
US20030073744A1 (en) 2003-04-17
BR0002381A (pt) 2000-11-07
SE0001499D0 (sv) 2000-04-26
FI20000977A0 (fi) 2000-04-26
FI20000977A7 (fi) 2000-10-27
GR1003591B (el) 2001-05-22
AU3011300A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
JP2002522485A5 (da)
JP2002532392A5 (da)
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
ATE146677T1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
RU2009123536A (ru) Стабильные парентеральные составы, включающие ингибиторы pcb на основе бензодиазепина
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
Chase et al. Hypothalamic releasing factors and Parkinson disease
SK7532002A3 (en) Pharmaceutical formulations containing zolmitriptan
RU2002122084A (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств
CH670763A5 (da)
US20150352038A1 (en) A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder
JP2002540148A5 (da)
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
DK200000687A (da) Middel til forsøgelse af afgivelsen af cerebral acetylcholin
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법
KR890004705A (ko) 항바이러스성 제제
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
JP2011111418A (ja) 口腔内局所投与に適したウイルス感染予防製剤
EP0402208B1 (fr) Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique
JP2003523385A5 (da)

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment